checkAd

    EQS-Adhoc  498  0 Kommentare LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service - Seite 2


    Phone: +41 43 268 32 35 / +41 79 410 81 88
    E-mail: investor-relations@lifewatch.com


    About LifeWatch AG:
    LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),

    Switzerland, is a leading healthcare technology and solution company,
    specializing in advanced digital health systems and wireless remote
    diagnostic patient monitoring services. LifeWatch's services provide
    physicians with critical information to determine appropriate treatment and
    thereby improve patient outcomes. LifeWatch AG has operative subsidiaries
    in the United States, in Switzerland and in Israel, and is the parent
    company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd.
    LifeWatch Services, Inc. is a leading U.S.-based provider of cardiac
    monitoring services and home sleep testing of Obstructive Sleep Apnea
    (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer
    and manufacturer of telemedicine products. For additional information,
    please visit www.lifewatch.com.

    Sign up for customized e-mail alerts and documentation requests at
    http://www.irlifewatch.com/alert-service.aspx

    This press release includes forward-looking statements. All statements
    other than statements of historical facts contained in this press release,
    including statements regarding future results of operations and financial
    position, the business strategy, and plans and objectives for future
    operations, are forward-looking statements. The words "believe," "may,"
    "will," "estimate," "continue," "anticipate," "intend," "expect" and
    similar expressions are intended to identify forward-looking statements.
    LifeWatch AG has based these forward-looking statements largely on current
    expectations and projections about future events and financial trends that
    it believes may affect the financial condition, results of operations,
    business strategy, short-term and long-term business operations and
    objectives, and financial needs. These forward-looking statements are
    subject to a number of risks, uncertainties and assumptions. In light of
    these risks, uncertainties and assumptions, the forward-looking events and
    circumstances described may not occur and actual results could differ
    materially and adversely from those anticipated or implied in the
    forward-looking statements. All forward-looking statements are based only
    on data available to LifeWatch AG at the time of the issue of this press
    release. LifeWatch AG does not undertake any obligation to update any
    forward-looking statements contained in this press release as a result of
    new information, future events or otherwise.

    THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
    Seite 2 von 3



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-Adhoc LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service - Seite 2 EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Regulatory Approval LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service 09.02.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible …